GTx, Inc. (GTXI) Reports Q4 Loss of $0.44/Share

GTx, Inc. (NASDAQ: GTXI) reported Q4 EPS of ($0.44), versus ($0.40) reported last year.

-- Enobosarm demonstrated clinical benefit and met the primary efficacy endpoint for the 9 mg dose cohort in GTx’s ongoing ER+/AR+ Phase 2 breast cancer trial --

-- Company expects to report preliminary results from its Phase 2 clinical trial of enobosarm to treat Stress Urinary Incontinence (SUI) in the third quarter of 2017 --

-- Company expects to begin an initial clinical study of a Selective Androgen Receptor Degrader (SARD) in men with castration-resistant prostate cancer in the second half of 2017 --

For earnings history and earnings-related data on GTx, Inc. (GTXI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Optimum Communications gets NYSE non-compliance notice over stock price
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c